Quick Answer
GeneDx Holdings Corp. reported Cash and Equivalents of $105.00 million for fiscal year 2025.
GeneDx Holdings Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $105.00M | +23.2% |
| 2024 | $85.21M | -14.5% |
| 2023 | $99.68M | -19.6% |
| 2022 | $123.93M | -69.1% |
| 2021 | $400.57M | -13.2% |
| 2021 | $461.28M | +1640.6% |
| 2021 | $26.50M | -54.8% |
| 2021 | $58.65M | -45.8% |
| 2020 | $108.13M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $95.97M | +65.8% | +29.5% |
| June 30, 2025 | $74.12M | +32.2% | -25.7% |
| March 31, 2025 | $99.70M | +19.2% | +17.0% |
| December 31, 2024 | $85.21M | -14.5% | +47.2% |
| September 30, 2024 | $57.89M | -33.7% | +3.2% |
| June 30, 2024 | $56.08M | -64.2% | -33.0% |
| March 31, 2024 | $83.67M | -58.6% | -16.1% |
| December 31, 2023 | $99.68M | -19.6% | +14.1% |
- GeneDx Holdings Corp. showed an increase of +23.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, GeneDx Holdings Corp.’s cash and equivalents has declined by 2.9% (from $108.13 million to $105.00 million).
- The most recent figure is from GeneDx Holdings Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: